Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP3440)
Name
Propolis
Species Origin Streptophyta ...     Click to Show/Hide
Streptophyta
Kingdom: Metazoa
Phylum: Arthropoda
Class: Insecta
Order: Hymenoptera
Family: Apidae
Genus: Apis
Species: Apis mellifera
Disease Diabetes mellitus [ICD-11: 5A10] Phase 4 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Resistance can be Reversed by This NP
          Ceftriaxone      Bacterial infection     Click to Show/Hide the Molecular Data of This Drug
                 Reversing Drug Resistance     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Escherichia coli isolates NECS892841 Microorganism model Escherichia coli
Escherichia coli isolates NECS30090 Microorganism model Escherichia coli
Escherichia coli isolates NECS858785 Microorganism model Escherichia coli
Escherichia coli isolates NECS864598 Microorganism model Escherichia coli
Escherichia coli isolates NEC892420 Microorganism model Escherichia coli
Escherichia coli isolates NEC118564 Microorganism model Escherichia coli
                    Experimental
                    Result(s)
Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.
          Ertapenem      Bacterial infection     Click to Show/Hide the Molecular Data of This Drug
                 Reversing Drug Resistance     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Escherichia coli isolates NECS892841 Microorganism model Escherichia coli
Escherichia coli isolates NECS30090 Microorganism model Escherichia coli
Escherichia coli isolates NECS858785 Microorganism model Escherichia coli
Escherichia coli isolates NECS864598 Microorganism model Escherichia coli
Escherichia coli isolates NEC892420 Microorganism model Escherichia coli
Escherichia coli isolates NEC118564 Microorganism model Escherichia coli
                    Experimental
                    Result(s)
Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.
          Ofloxacin      Bacterial infection     Click to Show/Hide the Molecular Data of This Drug
                 Reversing Drug Resistance     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Escherichia coli isolates NECS892841 Microorganism model Escherichia coli
Escherichia coli isolates NECS30090 Microorganism model Escherichia coli
Escherichia coli isolates NECS858785 Microorganism model Escherichia coli
Escherichia coli isolates NECS864598 Microorganism model Escherichia coli
Escherichia coli isolates NEC892420 Microorganism model Escherichia coli
Escherichia coli isolates NEC118564 Microorganism model Escherichia coli
                    Experimental
                    Result(s)
Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.
References
Reference 1 ClinicalTrials.gov (NCT02794506) Propolis Improves Glycemic Control in Subjects With Type 2 Diabetes and Chronic Periodontitis
Reference 2 Synergistic Effect of Propolis and Antibiotics on Uropathogenic Escherichia coli. Antibiotics (Basel). 2020 Oct 27;9(11):739.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China